Native collagen type II and Aflapin® in the management of hip and knee osteoarthritis: a single-centre prospective observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260750Keywords:
Osteoarthritis, Native collagen type II, Aflapin, Pain, Stiffness, Global assessmentAbstract
Background: Osteoarthritis (OA) affects over 595 million people worldwide, with cases rising by 132% from 1990. Standard NSAID therapy offers only symptomatic relief and has safety limits, driving interest in alternatives. Native type II collagen and Aflapin provide complementary immunomodulatory and anti-inflammatory effects. This study evaluates their combined efficacy and safety in hip or knee OA over 12 weeks.
Methods: Adults (≥40 years) with confirmed hip or knee OA receiving native collagen type II 40 mg + Aflapin 100 mg as routine treatment were enrolled after consent. Key exclusions were recent corticosteroid/NSAID or intra-articular therapy, major comorbidities, obesity, pregnancy, or any other investigational drug use. Efficacy and safety were assessed via 100 mm VAS for pain and stiffness and a 5-point Likert scale for global OA status at weeks 4 and 12.
Results: A total of 100 subjects (mean age 58.6 years; 57% female) were enrolled. Significant improvements in pain, stiffness, and overall OA status were observed by weeks 4 and week 12, with all subjects reporting pain relief and 99% showing reduced stiffness by week 12. No rescue medication was needed, and three minor adverse events (AEs) (headache, bloating, mild gastritis) resolved without treatment.
Conclusions: Native collagen type II 40 mg + Aflapin 100 mg significantly improved joint pain, stiffness, and overall OA status by Week 4, with further gains by Week 12. No rescue medication was needed, and only mild, self-limiting AEs occurred. The combination was well tolerated and effective for knee or hip OA symptom relief.
Metrics
References
Xie X, Zhang K, Li Y, Li Y, Li X, Lin Y, Huang L, Tian G. Global, regional, and national burden of osteoarthritis from 1990 to 2021 and projections to 2035: A cross-sectional study for the Global Burden of Disease Study 2021. PLoS One. 2025;20(5):e0324296. DOI: https://doi.org/10.1371/journal.pone.0324296
Li Z, Chen Y, Shen Z. Global shifts in osteoarthritis subtype trends among older adults due to elevated BMI: an age-period-cohort analysis based on the global burden of disease database. Frontiers in Public Health. 2025;13:1518572. DOI: https://doi.org/10.3389/fpubh.2025.1518572
Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, et al. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatol. 2023;5(9):e508-22.
Zhang X, Huang C, Hu Z, Tan Y, Wang P, Zhu L, Kang J. Global, regional, and country-specific lifetime risks of osteoarthritis, 1990-2021: a systematic analysis for the global burden of disease study 2021. Global Health Res Policy. 2025;10(1):29. DOI: https://doi.org/10.1186/s41256-025-00419-9
Zhao Y, Wang J, Zhao B, Zhang Y. The impact of high BMI on the global burden of osteoarthritis from 1990 to 2021 and future projections. Front Med. 2025;12:1561750. DOI: https://doi.org/10.3389/fmed.2025.1561750
World Health Organization. Osteoarthritis-Fact Sheet. 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/osteoarthritis. Accessed on 15 February 2026.
Magni A, Agostoni P, Bonezzi C, Massazza G, Menè P, Savarino V, et al. Management of osteoarthritis: expert opinion on NSAIDs. Pain Therapy. 2021;10(2):783-808. DOI: https://doi.org/10.1007/s40122-021-00260-1
D’Adamo S, Cetrullo S, Panichi V, Mariani E, Flamigni F, Borzì RM. Nutraceutical activity in osteoarthritis biology: A focus on the nutrigenomic role. Cells. 2020;9(5):1232. DOI: https://doi.org/10.3390/cells9051232
Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals. 2020;10(4):697. DOI: https://doi.org/10.3390/ani10040697
Gupta A, Maffulli N. Undenatured type II collagen for knee osteoarthritis. Ann Med. 2025;57(1):2493306. DOI: https://doi.org/10.1080/07853890.2025.2493306
Verma R, Nath R, Jain K, Mehra A, Mehta K, Dsouza L, et al. Mechanisms of action of native collagen type II and Aflapin® on the pathophysiology of osteoarthritis and their evidences. Int J Res Orthop. 2024;10(5):1098-107. DOI: https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20241946
Jain K, Mehra A, Mehta K, Dsouza L, Kumar R. Role of undenatured collagen type II and Aflapin combination in the management of osteoarthritis: A review. Int J Res Orthop. 2021;7:885. DOI: https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20212441
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutrit J. 2015;15(1):14. DOI: https://doi.org/10.1186/s12937-016-0130-8
Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615. DOI: https://doi.org/10.7150/ijms.8.615
Karlapudi V, Sunkara KB, Konda PR, Sarma KV, Rokkam MP. Efficacy and safety of Aflapin®, a novel Boswellia serrata extract, in the treatment of osteoarthritis of the knee: A short-term 30-day randomized, double-blind, placebo-controlled clinical study. J Am Nutr Assoc 2023;42(2):159-68. DOI: https://doi.org/10.1080/07315724.2021.2014370
Stabile M, Fracassi L, Lacitignola L, Garcia-Pedraza E, Girelli CR, Calculli C, et al. Effects of a feed supplement, containing undenatured type II collagen (UC II®) and Boswellia Serrata, in the management of mild/moderate mobility disorders in dogs: A randomized, double-blind, placebo controlled, cross-over study. Plos one. 2024;19(10):e0305697. DOI: https://doi.org/10.1371/journal.pone.0305697
Zapata A, Fernández-Parra R. Management of osteoarthritis and joint support using feed supplements: A scoping review of undenatured type II collagen and Boswellia serrata. Animals. 2023;13(5):870. DOI: https://doi.org/10.3390/ani13050870
Downloads
Published
How to Cite
Issue
Section
